ArticleQuantitative imaging in medicine and surgery2026
Clinical and neuroradiologic spectrum of glutaric acidemia type 1 in children: insights from a retrospective cohort in Guangdong Province, China.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glutaric acidemia type 1 (GA-1) is a rare autosomal recessive metabolic disorder resulting from a deficiency in glutaryl-CoA dehydrogenase (GCDH). Current evidence indicates that GA-1 remains under-recognized by clinicians, a factor that may contribute to delayed diagnosis. The aim of this study was to retrospectively analyze the clinical manifestations and imaging characteristics of GA-1. Methods: This study enrolled patients diagnosed with GA-1 at the Guangzhou Women and Children's Medical Center between April 2014 and April 2024. Clinical data related to GA-1 were retrieved through the electronic medical record system, and magnetic resonance imaging (MRI) scans were collected for all patients. Cranial MRI images were independently evaluated by two radiologists (with 10 and 6 years of experience in pediatric neuroimaging diagnosis, respectively) using a blinded approach. Blood acylcarnitine levels were analyzed using tandem mass spectrometry, urinary organic acid concentrations were quantified via gas chromatography-mass spectrometry, and Results: This study enrolled 24 GA-1 children (8 males, 16 females) from Guangdong Province, China. Diagnosis was confirmed by elevated glutaric acid (GA), 3-hydroxyglutaric acid (3-HGA), and glutarylcarnitine (C5DC) levels, with increased C5DC/octanoylcarnitine (C8) and C5DC/propionylcarnitine (C3) ratios. Genetic analysis identified 12 GCDH mutations in 11 patients, including 5 novel variants (c.395G>A, c.271+1G>A, c.1156C>G, c.146_149delACTG, and c.1011A>G). Neuroimaging revealed abnormal brain MRI findings in all patients (100%), predominantly featuring frontotemporal extracerebral space widening (75.0%, 18/24) and symmetric basal ganglia hyperintensity (83.3%, 20/24). These findings align with the established GA-1 phenotypes. Conclusions: This study underscores the need for heightened awareness of GA-1 among clinicians and radiologists, characterizes its MRI signature, and expands the GCDH mutation spectrum with five novel variants, thereby offering valuable guidance for imaging-based diagnosis and genetic counselling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.